neurology

News

Prilenia eyes 2025 launch for Huntington’s drug pridopidine

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial.

News

Justin Klee and Joshua Cohen, co-CEOs of Amylyx Pharma

Amylyx plummets as confirmatory trial of ALS drug fails

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putti

News

AbbVie’s 24-hour Parkinson’s therapy to roll out on NHS

Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous i

News

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA)

News

Could the next Alzheimer’s drug discovery be… Viagra?

Epidemiological studies can often throw out intriguing and sometimes erroneous correlations between a variable and a disease, but UK scientists say a finding that Alzheime

News

Lundbeck study knocks confidence in alpha-syn as CNS target

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), althou

Prilenia eyes 2025 launch for Huntington’s drug pridopidine

Amylyx plummets as confirmatory trial of ALS drug fails

AbbVie’s 24-hour Parkinson’s therapy to roll out on NHS

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

Could the next Alzheimer’s drug discovery be… Viagra?

Lundbeck study knocks confidence in alpha-syn as CNS target

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

neurology

Editor's Picks